The effects of CD44 down-regulation on stem cell properties of head and neck cancer cell lines

Journal of Oral Pathology and Medicine

Volumn 42, Issue 9, 2013, Pages 682-690

  Kidwai, Fahad ^a   Costea, Daniela E ^b   Hutchison, Iain ^c   Mackenzie, Ian ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF BERGEN   (Norway)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer stem cells; CD44; Head and neck cancers

Indexed keywords

BUTYRIC ACID; CD44V ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4;

ARTICLE; CANCER STEM CELL; CELL EXPANSION; CELL FATE; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

CANCER STEM CELLS; CD44; HEAD AND NECK CANCERS;

ANTIGENS, CD44; BUTYRIC ACID; CARCINOMA, SQUAMOUS CELL; CELL COUNT; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84885915731     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12076     Document Type: Article

References (52)

1. Mackenzie IC. Relationship between mitosis and the ordered structure of the stratum corneum in mouse epidermis. Nature 1970; 226: 653-5.
2. Potten CS. The epidermal proliferative unit: the possible role of the central basal cell. Cell Tissue Kinet 1974; 7: 77-8.
3. Mascre G, Dekoninck S, Drogat B, et al. Distinct contribution of stem and progenitor cells to epidermal maintenance. Nature 2012; 489: 257-62.
4. Potten CS. Stem cells: their identification and characterization. Cambridge: Churchill Livingstone, 1983.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
6. Sell S. Potential gene therapy strategies for cancer stem cells. Curr Gene Ther 2006; 6: 579-91.
7. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
8. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44.
9. Mannelli G, Gallo O. Cancer stem cells hypothesis and stem cells in head and neck cancers. Cancer Treat Rev 2012; 38: 515-39.
10. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
11. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-8.
12. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
13. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158-63.
14. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
15. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 2008; 68: 1820-5.
16. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
17. Locke M, Heywood M, Fawell S, Mackenzie IC. Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 2005; 65: 8944-50.
18. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44 + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696-708.
19. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44 + breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777-85.
20. Harper LJ, Piper K, Common J, Fortune F, Mackenzie IC. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 2008; 36: 594-603.
21. Harper LJ, Costea DE, Gammon L, Fazil B, Biddle A, Mackenzie IC. Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer 2010; 10: 166-82.
22. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006; 124: 1111-5.
23. Wang SJ, Bourguignon LY. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006; 132: 771-8.
24. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254-67.
25. Tijink BM, Buter J, De Bree R, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006; 12: 6064-72.
26. Khan SA, Cook AC, Kappil M, et al. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 2005; 22: 663-73.
27. Wang SJ, Wreesmann VB, Bourguignon LY. Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer. Head Neck 2007; 29: 550-8.
28. Bauer JA, Trask DK, Kumar B, et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther 2005; 4: 1096-104.
29. Prime SS, Nixon SV, Crane IJ, et al. The behaviour of human oral squamous cell carcinoma in cell culture. J Pathol 1990; 160: 259-69.
30. Barshishat M, Levi I, Benharroch D, Schwartz B. Butyrate down-regulates CD44 transcription and liver colonisation in a highly metastatic human colon carcinoma cell line. Br J Cancer 2002; 87: 1314-20.
31. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003; 133: 2485S-93S.
32. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33-45.
33. Bloor BK, Jelvagharan M, White KN, Odell EW. Characterization of CD44 splicing patterns in normal keratinocytes, dysplastic and squamous carcinoma cell lines. Int J Oncol 2001; 18: 1053-9.
34. Bloor BK, Rajarajan A, Jaafary-Haghighat K, Odell EW. Transcription and expression of CD44 variant exons by oro-pharyngeal squamous cell carcinomas. Int J Oncol 2002; 21: 907-13.
35. Mack B, Gires O. CD44s and CD44v6 expression in head and neck epithelia. PLoS ONE 2008; 3: e3360.
36. Wang SJ, Bourguignon LY. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol 2011; 178: 956-63.
37. Wang SJ, Wong G, De Heer AM, Xia W, Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009; 119: 1518-30.
38. Biddle A, Liang X, Gammon L, et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 2011; 71: 5317-26.
39. Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012; 287: 32800-24.
40. Hennig G, Behrens J, Truss M, Frisch S, Reichmann E, Birchmeier W. Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoter in vivo. Oncogene 1995; 11: 475-84.
41. Liu J, Bi G, Wen P, et al. Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol 2007; 4: 59-63.
42. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004; 14: 43-7.
43. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006; 98: 1755-7.
44. Facompre N, Nakagawa H, Herlyn M, Basu D. Stem-like cells and therapy resistance in squamous cell carcinomas. Adv Pharmacol 2012; 65: 235-65.
45. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-59.
46. Borjesson PK, Postema EJ, Roos JC, et al. Phase I therapy study with (186) re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2003; 9: 3961S-72S.
47. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010; 46: 1271-7.
48. Oliveira DT, Odell EW. Expression of CD44 variant exons by normal oral epithelia. Oral Oncol 1997; 33: 260-2.
49. Oliveira DT, Sherriff M, Odell EW. Expression of CD44 variant exons by primary and metastatic oral squamous carcinomas. J Oral Pathol Med 1998; 27: 303-7.
50. Hoey T, Yen WC, Axelrod F, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009; 5: 168-77.
51. Cassell A, Grandis JR. Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs 2010; 19: 709-22.
52. Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 2009; 115: 922-35.